← Browse by Condition
Medical Condition

glioblastoma multiforme

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for glioblastoma multiforme sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — glioblastoma multiforme Clinical Trials

How many clinical trials are currently recruiting for glioblastoma multiforme?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for glioblastoma multiforme, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for glioblastoma multiforme?
glioblastoma multiforme research spans Phase 1 (4 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a glioblastoma multiforme clinical trial?
Eligibility criteria for glioblastoma multiforme trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
3
Top Sponsors
Phost'In Therapeutics 1 trial
National Institute of Neurological Disorders and Stroke (NINDS) 1 trial
Northwell Health 1 trial
Jonsson Comprehensive Cancer Center 1 trial
Guoqiang Yu 1 trial

Recruiting Clinical Trials

NCT05495295 Phase 1
Recruiting
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Enrollment
149 pts
Location
France, Italy
Sponsor
Phost'In Therapeutics
View Trial →
NCT07416188 Phase 1, Phase 2
Recruiting
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Enrollment
40 pts
Location
United States
Sponsor
National Institute of Neurolog...
View Trial →
NCT05979064
Recruiting
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Enrollment
10 pts
Location
United States
Sponsor
Northwell Health
View Trial →
NCT06059690 Phase 1, Phase 2
Recruiting
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Enrollment
50 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
View Trial →
NCT04780009
Recruiting
Loupe-Based Intraoperative Fluorescence Imaging
Enrollment
30 pts
Location
United States
Sponsor
Guoqiang Yu
View Trial →
NCT03911388 Phase 1
Recruiting
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Enrollment
24 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT05864534 Phase 2
Recruiting
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Enrollment
25 pts
Location
United States
Sponsor
Northwestern University
View Trial →

Related Conditions

glioma (2) gbm (2) high grade glioma (2) glioma malignant (2) brain cancer (2) malignant tumor (1) advanced solid tumor (1) metastatic cancer (1) recurrent glioblastoma (1) glioblastoma idh isocitrate dehydrogenase wildtype (1) relapsed cancer (1) recurrent tumor (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology